Context

Triton completed an investment in Bergman Clinics alongside existing shareholders NPM Capital and the Malenstein family, who both retained minority positions in the business. The transaction followed a competitive sale process mandated to JP Morgan and Axeco Corporate Finance, which attracted interest from TowerBrook Capital Partners, Cinven, Bain Capital, and BC Partners before Triton emerged as the winning bidder. The process had originally been launched in early 2020 but was put on hold due to the COVID-19 pandemic before being revived in September 2020. Triton's investment is intended to support Bergman Clinics' continued geographic expansion, as well as investment in technological innovation, digitisation, and staff training.

Target

Bergman Clinics is one of the leading chains of independent specialist outpatient clinics in Europe, founded nearly 30 years prior to the transaction and headquartered in Naarden, Netherlands. The group operates 140 focus clinics across five countries — the Netherlands, Sweden, Denmark, Norway, and Germany — treating more than 300,000 patients per year, supported by more than 3,000 employees and over 250 medical specialists. Bergman Clinics is a multi-specialty outpatient platform offering high-quality, plannable elective medical care across a broad range of specialties including orthopaedics, ophthalmology, gynaecology, aesthetic medicine, cardiology, gastroenterology, dermatology, and vascular medicine.